CDC revised RSV guidelines to include ages 50-59, boosting Moderna stock by nearly 6%.

From Zacks Investment Research: 2025-07-03 10:22:00

The CDC revised RSV guidance to include high-risk individuals aged 50-59, expanding eligibility for Moderna’s RSV vaccine, mResvia. Moderna’s stock rose nearly 6% after the CDC’s new recommendations. The expanded guidance widens Moderna’s addressable market, with mResvia now recommended for adults aged 18-59. Despite launching last year, mResvia sales were modest due to late approval. GSK and Pfizer currently lead the RSV vaccine market, with broader access potentially helping Moderna close the gap. Moderna currently holds a Zacks Rank #3 (Hold) status.



Read more at Zacks Investment Research: MRNA Stock Jumps on CDC’s Revised RSV Vaccine Recommendations – July 3, 2025